The University of Chicago Medicine and AbbVie have extended their collaboration through 2027 to support cancer research and clinical trials. The agreement builds on a partnership begun in 2016 and aims to accelerate translational and clinical research to improve patient outcomes.
The extension is intended to advance therapeutic innovation and streamline clinical trial operations, increasing connectivity between clinicians and researchers at both organizations. The partnership will also benefit from enhanced infrastructure as UChicago Medicine prepares to open the AbbVie Foundation Cancer Pavilion in 2027, Illinois’ first freestanding cancer center with dedicated clinical trial spaces and state-of-the-art research facilities.
“The AbbVie‑UChicago Medicine collaboration has created valuable opportunities for deep and meaningful scientific discussion and the development of clinical trials for cancer treatment,” said Kunle Odunsi, MD, PhD, director of the University of Chicago Medicine Comprehensive Cancer Center. “This partnership is an exceptional model of industry and academia working together with a patient‑centered focus.”
“Our partnership with the University of Chicago is driven by our shared dedication to advancing cancer research and clinical innovation,” said Andrew Souers, PhD, vice president, oncology discovery research at AbbVie. “We look forward to deepening our long‑standing collaboration to continue delivering meaningful, lasting impact for people living with cancer.”
The University of Chicago Medicine Comprehensive Cancer Center is one of two NCI‑designated Comprehensive Cancer Centers in Illinois and has held that designation since 1974. For more than 50 years, the center has contributed to major advances in cancer care, including developments in chemotherapy, hormonal therapy, gene therapy, and bone marrow transplantation.
Leave a Reply